Pharma commercial operations across GCC, South Asia, and Europe — field sales, business development, field force strategy, and commercial program leadership. Specialisation in rare disease, specialty, and market access.
IIM Ahmedabad · Ex-ZS Associates · Ex-Novartis · 20+ years
LinkedIn ↗Lecanemab versus donanemab in early AD. CMS amyloid-confirmation coverage and ARIA monitoring as the access gate.
US NSCLC segments by histology and biomarker before it segments by drug. This maps where patients are actually diagnosed and tested, and where the gap between diagnosis and treatment costs them.
Iptacopan oral pivot versus the anti-C5 IV class. Orphan-drug exclusion from IRA negotiation (US), NICE HST (UK) and SFDA lag (GCC).
From zero disease-specific drugs to five in three years: how endothelin, complement and APRIL inhibitors are redrawing the IgAN market.
Tafamidis is shielded from IRA negotiation by the orphan-drug exclusion. ICER judged its ~$268K price ~85–95% too high, and acoramidis plus pending generics are the real net-price levers.
HAE pathophysiology, the Type I/II split, attack burden and the diagnostic-delay problem that defines the US in-market landscape.
Gene-therapy access at $2.2–3.1M, the CMS Cell & Gene Therapy Access Model, VOC-freedom endpoints, and the hydroxyurea step-edit.
US incidence 1 in 15,700, de novo SCN1A genetics, and one of the highest SUDEP rates documented in epilepsy.
Fabry disease splits into classic childhood-onset and a largely undiagnosed later-onset cardiac form. An X-linked organ timeline and the ~35–50% amenable-mutation gate decide who is treatable.
IV enzyme replacement buy-and-bill under Part B vs oral SRT under Part D, the CYP2D6 PA gate, and generic miglustat.
Fenfluramine leads on efficacy, cannabidiol anchors the lower-cost branded option, and stiripentol holds the adjunct niche.
Two next-generation ERTs are moving to displace alglucosidase alfa in US late-onset Pompe disease. Avalglucosidase alfa and cipaglucosidase alfa plus miglustat now define the competitive set.
Why Rezdiffra's $47,400 WAC lands inside ICER's value range, why the IRA reset hits semaglutide first, and how Part D routing shapes MASH access.
CMS's coverage-with-evidence-development registry, not IRA negotiation, is the anti-amyloid access gate. ICER's below-value verdict and Part B routing set the rest.
COPD is a large, under-diagnosed, exacerbation-driven US disease that has just become biomarker-stratified. The blood eosinophil count now decides which of ~14 million diagnosed adults can reach a biologic.
US access to plaque psoriasis biologics is gated by step therapy and reshaped by two forces landing together. IRA price negotiation on Stelara and Enbrel, and biosimilar erosion of adalimumab and ustekinumab.
NSCLC is a specialist, buy-and-bill oncology market, not a mass-reach primary-care one. A concentrated medical-oncology prescriber base, biomarker-gated prescribing, and infused immuno-oncology under Medicare Part B dictate a small, account-based key-account and MSL field model.
GCC HAE management is acute-only, with prophylaxis penetration near zero. More than 85% of patients are undiagnosed, and NPHC coverage for lanadelumab would be the access trigger for the region's largest market.
The UK Pompe Consortium registry counts roughly 200 confirmed patients. Total estimated prevalence, including the undiagnosed pool, runs 350-450. Within the confirmed, treated population, 30-50 are ADA-positive inadequate responders and 80-120 are on home ventilation.
A 37-centre national survey confirms 1,152 UK HAE type I/II patients. A top-down 1:32,000 prevalence rate implies roughly 2,000, and the UK HAE Alliance's broader planning estimate runs to 5,000-6,000, of which only 1,500-2,000 are on prophylaxis today.
The UK SMA population is not one number. A ~1,000-patient actively-monitored NHS cohort and a 1,800-2,000-patient total prevalence estimate both appear across UK sources, and the gap between them is the pre-NBS legacy population outside the four specialist networks' active census.
All three SMA mechanisms are formulary-listed across the GCC. Outcomes-based rebate contracts now anchor Zolgensma's ~$1.5-1.8M price to a 24-month motor milestone, after an NBS expansion generating 60-80 new gene-therapy candidates a year.
The 1,400–2,000-patient refractory Dravet cohort is the opening. REMS-free cardiac safety and a 45%-Medicaid access plan decide who reaches it.
NPHC's KSA-first coverage model sets the de facto GCC access bar for anti-C5 agents. Iptacopan faces a 12-24 month SFDA registration queue before NPHC even evaluates it.
GCC HAE access is structurally two-tier: broad acute coverage, but a prophylaxis bar few clear. Only 30-40% of applicants clear NPHC's individual-case prophylaxis review, and private insurance beats the NPHC pathway on speed.
NICE's accepted cost-effectiveness case for budesonide (TA937, updated by TA1128) rests on a 5–8 year modelled ESRD delay. The same mandatory ACEi/ARB gate applied to sparsentan narrows the UK's eligible IgA nephropathy population from 10,000–15,000 to 3,000–5,000 patients.
GCC tafamidis costs roughly a tenth of its US price, yet uptake is not limited by affordability. Tc-PYP scintigraphy access at fewer than 8 GCC centres is the real constraint.
NPHC has a 72%-cost-reduction incentive to switch amenable-mutation Fabry patients from ERT to migalastat. A single HEK293 assay lab in the entire GCC is the only thing standing in the way.
An estimated 8,000-9,000 Americans live with hereditary angioedema. Just 35-40% receive any prophylaxis, leaving 2,500-4,000 patients who meet treatment criteria untreated, the funnel this model sizes precisely.
Sutimlimab's CARDINAL trial left 46% of patients without a haemoglobin response. The two most-advanced next-generation complement inhibitors then abandoned cold agglutinin disease after its launch, leaving the entry gap defined by non-response and cost, not a clinical rival.
15,000-20,000 Americans carry a PNH clone, but only about 3,500 reach complement-inhibitor therapy. Up to 1,200 of them stay anaemic on it. This model sizes every gap in between.
The GCC SMA market already has three NPHC-covered agents spanning Types 1-3. A new entrant has exactly two open niches: the Zolgensma-attenuation cohort, or undiagnosed adult-onset Type 4.
NICE recommended both Dravet therapies through standard Technology Appraisal, not the ultra-rare HST route. This covers what the Fintepla Cardiac Monitoring Scheme costs the NHS, and why the UK treatment algorithm is now closed to new entrants without a significant clinical edge.
Binding constraint: capture newly diagnosed ATTR-CM volume and survive ICER's steepest value gap in the rare-disease basket.
The National Amyloidosis Centre holds the clinical-expert seat at every NICE ATTR appraisal to date. This workbook sizes the UK ATTR KOL network before a name enters it: NAC's 400-500-patient ATTRv surveillance registry, the separate UCL and Queen Elizabeth Hospital Birmingham National ATTRv Registry tracking approximately 800 patients, and the roughly 30 NHS centres running Tc-PYP scintigraphy nationally.
Four London teaching hospitals anchor roughly 6,000 of the UK's 15,000-17,000 sickle cell patients. Barts, King's, Imperial and Homerton, with Birmingham Heartlands, Manchester, Bristol and Nottingham forming the next ring. That eight-centre structure is exactly the institutional signal this workbook sizes before any individual name enters it.
GCC anti-C5 tender pricing already runs 40-60% of US WAC, anchored to whichever EU comparator prices lowest. A further 10-20% negotiation discount compounds it. Iptacopan has to clear the same cascade, still 12-24 months from SFDA registration.
Four NHS Highly Specialised Services networks and six designated gene-therapy centres carry the UK SMA treatment pathway. This workbook sizes that institutional structure, plus the Bristol Institute of Child Health attenuation-cohort follow-up, before any physician name enters it.
HAS reimburses iptacopan second-line only, after at least six months on a C5 inhibitor, while ravulizumab holds first-line. France split the anti-complement class by line of therapy, not by price.
NICE's SCD gene therapy appraisal may be the largest NHS rare disease budget event in history. It hinges on an annuity payment model that current NHS SCD management cost cannot yet clearly justify.
Agalsidase beta runs an estimated £150-250K per patient per year against migalastat's £80-120K. NICE has quantified that £70-130K annual switch saving but the NHS has not captured it at scale, and pegunigalsidase's TA915 commercial arrangement now sets a third price point.
NICE's accepted 20-35% PAS discount off budesonide's WAC sets the pricing floor sparsentan already clears. The £140-180M NHS budget ceiling applies once the ACEi/ARB gate narrows eligibility to 3,000-5,000 patients.
France's PMSI hospitalisation database identified 897 PNH patients between 2018 and 2022, putting prevalence near 1 in 94,000. That is below the 1-in-70,000-to-80,000 range Orphanet and France's national rare disease plan have long cited.
NPHC pays roughly SAR 1.2-2.4M per patient per year for enzyme replacement against SAR 400-600K for migalastat. That 72% differential gives NPHC a direct incentive to switch eligible patients, capped almost entirely by a single-laboratory diagnostic bottleneck rather than by price.
The thyroid-disease diagnostic confounder, specialist neurologist concentration, and the FcRn antagonist access pathway across GCC neurology practice.
Casgevy and Lyfgenia list at $2.2M and $3.1M, but the sticker price is not what gets paid. CMS's Cell and Gene Therapy Access Model, Medicaid concentration, and a $1.5-1.9M ICER ceiling decide the realised net.
NICE recommended crizanlizumab in 2021, then withdrew the guidance in 2023 when the confirmatory trial failed. The licence was revoked. In UK sickle cell, price is not the binding constraint. Confirmatory evidence is.
Lanadelumab lists near $450,000 a year against berotralstat's roughly $95,000. ICER's 2021 fair-value benchmark for berotralstat lands almost exactly on that list price, and the three 2025 entrants carry no ICER anchor of their own.
Near-universal newborn screening puts the UK's 15,000-17,000 SCD patients on the registry with confidence. But only the 4,000-6,000 hydroxycarbamide-inadequate subset is the addressable population for a new non-gene agent.
All three SMA therapies cleared NICE with confidential PAS. The UK's 2021 newborn screening programme is now the real access lever, shifting competition to physician and family preference.
HAE family cascade screening opportunity, laryngeal attack burden, and the prophylactic therapy access gap across GCC specialist centres.
NICE's June 2025 rejection of efgartigimod (TA1069) leaves UK myasthenia gravis with no NICE-recommended novel agent. Eculizumab's own appraisal (TA636) was withdrawn by the manufacturer in 2020 without a cost-effectiveness verdict, and the NHS IVIg cost-offset argument is now the strongest lever for a future resubmission.
A fourth SMA drug has no room in the broad market — the opening is the 500–700-patient Zolgensma-attenuation cohort with no PA pathway yet.
Just 10-15 neuromuscular neurologists across six named GCC referral centres manage 70-80% of confirmed generalised myasthenia gravis. That concentration is exactly what this workbook sizes before any individual name enters it.
Bimekizumab already clears PASI 90 in 85% of patients at week 16. A new plaque psoriasis entrant has to win on dosing interval or route, not incremental clearance, against an incumbent price anchor the IRA has already cut 66-67%.
Three IV enzyme replacement brands run ~$300,000/year with no generic rival, so preferred-ERT designation is the real pricing lever. Eliglustat's CYP2D6 gate and generic miglustat's trial-first rule complete the picture.
Fewer than 25 consultants manage over 90% of the UK's PNH caseload. They sit across five NHS Highly Specialised Services centres anchored by the Leeds National PNH Service. That kind of institutional concentration is exactly the signal this workbook sizes before any individual name enters it.
GCC ATTR-CM burden runs 15,000-25,000 on a broad HFpEF-adjacent estimate, or 2,000-5,000 on the narrower ATTRwt-CM cohort. Fewer than 8 centres with scintigraphy capacity explain why so little of either total converts to a confirmed diagnosis.
Fabrazyme's orphan-drug exclusion under the IRA shields it from Medicare price negotiation entirely. No rebate or net-price figure is disclosed anywhere in the primary record for any Fabry therapy. The orphan exclusion, not a discount ladder, is what a Fabry pricing strategy has to be built around.
Two UK gMG estimates disagree by 3-4x on purpose. A narrower moderate-severe subgroup of roughly 4,000 from the MGA UK survey sits inside a broader 12,000-15,000 total prevalence figure that also counts mild, well-controlled cases the narrower estimate excludes.
Rezdiffra and Wegovy already hold the noncirrhotic F2-F3 label. The clearer opening for a new entrant is the compensated-cirrhosis boundary neither drug covers.
The NHS runs the most treatment-advanced Dravet pathway in Europe. Free SCN1A testing on GMS, a NICE-defined CBD-then-fenfluramine algorithm, and 25 paediatric epilepsy HSS centres underpin it.
Stelara's negotiated price falls to $4,695 from a $13,836 list, a 66% cut, effective January 2026. That is the same month ustekinumab biosimilars begin launching. Two separate pricing shocks land on one legacy biologic at once.
Sutimlimab costs $259,000-$302,000 per patient per year. A peer-reviewed analysis puts its ICER at $2.34M/QALY, with standard of care favoured in all 10,000 probabilistic-sensitivity iterations. The value gap, not a rival drug, sets the pricing discipline.
PNH diagnostic pathway, FLAER flow-cytometry bottleneck and the undiagnosed clonal pool across GCC specialist centres.
NICE's rejection of crizanlizumab on price alone is the binding constraint for any new SCD agent. 4,000-6,000 UK patients sit in a post-withdrawal white space, and the WAC ceiling decides whether you repeat that outcome.
The binding constraint for a new Dravet agent in the GCC is regulatory classification, not efficacy. Any agent must clear the SFDA Controlled Drug Board as non-controlled, because CBD-class compounds are permanently excluded.
Fintepla's weight-based list price runs roughly 3x Epidiolex. Payers work that gap through step-edit design layered on Part D pharmacy-benefit routing, and no generic cannabidiol reaches the US market before the late 2030s.
500,000+ US patients aged 70+ with HFpEF carry undiagnosed ATTRwt-CM, against only 70,000-100,000 diagnosed and treated. Two further sub-populations, Val122Ile carriers and ATTR-PN, remain even less visible.
Iptacopan already cleared Germany's AMNOG process with a substantial benefit finding and no comparator dossier. A new entrant without orphan-pathway standing has to win that same finding the hard way, through IQWiG.
A six-physician BIMDG subcommittee advises NICE directly on Pompe disease. It sits at the centre of a five-centre UK Pompe Consortium and an eight-centre NHS Highly Specialised Service network. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.
Both NHS-commissioned Dravet therapies cleared NICE's standard £20,000-30,000/QALY bar, not the ultra-rare HST threshold. A new entrant is held to the same bar the incumbents already cleared, and total NHS Dravet spend still runs a modest £9-16M.
The Renal Association's IgAN guideline committee, not any single physician, sets the reference point NICE checks against. This workbook sizes that committee and the network behind it before individual outreach begins.
France prices PNH on two tracks. Ravulizumab holds first-line; iptacopan is reimbursed second-line only, and reached patients through early access two weeks before its EU marketing authorisation took effect.
Tafamidis prices 12-17x above ICER's fair-value benchmark, yet the orphan-drug exclusion keeps it out of IRA negotiation. Acoramidis and pending generics, not Medicare, now set net price.
NICE's TA1121 cost-minimisation rule directs clinicians to whichever ATTR-CM stabiliser costs less. That rule, not the QALY threshold alone, now sets a new entrant's UK price ceiling.
Pompe ERT WAC runs near $400,000 a year, and the Pombiliti + Opfolda regimen splits across Medicare Part B and Part D. Zero ICER reviews exist today, with one expected in 2025 and a 12-month J-code lead time for any new entrant.
200-300 diagnosed GCC Fabry patients sit against a true prevalence estimated 3-5 times higher. A single regional laboratory gates the amenable-mutation test, and female heterozygotes are diagnosed at under half the male rate.
Generalised myasthenia gravis has no formal NPHC programme. Efgartigimod access runs through private insurance, fastest at 1-4 weeks, or hospital pharmacy committees, with NPHC engagement targeted for 2025-2026.
ICER priced efgartigimod's value at $18,300-28,400 a year, under half its ~$418,400 assumed launch price. That gap is hardening into a three-tier step-edit staircase across US commercial and Part B plans.
316,950 new US invasive breast cancer diagnoses in 2025. Only 6.0% present as metastatic at diagnosis, but 73.9% of the metastatic population is HR+/HER2-, the subtype this model is actually built to size.
NHS-commissioned alglucosidase alfa runs £200,000-350,000 per patient a year post-PAS. Avalglucosidase alfa's NICE TA821 recommendation carries a 20-30% WAC premium and a switch-population budget impact of just £2-4M a year.
No UK gMG biologic has ever cleared NICE at any price. Eculizumab's manufacturer withdrew before submitting an ICER, and efgartigimod's June 2025 rejection means a future entrant's price ladder starts from zero precedent, not a benchmark.
Zolgensma's $2.125M sticker price obscures the real US SMA pricing lever. A 10-state Medicaid outcomes-based annuity pays $212,500 a year for ten years, set against chronic Spinraza and Evrysdi costs and a Part B/Part D routing split that changes patient cost by drug.
National Amyloidosis Centre-anchored epidemiology puts UK ATTRwt-CM prevalence at 20,000-40,000. Only 3,000-4,000 patients are on NICE-commissioned tafamidis today, leaving 15,000-36,000 undiagnosed.
France reimburses iptacopan second-line only, after at least six months on a C5 inhibitor, while ravulizumab holds the first-line position. The restriction, not the price, is what defines the addressable population.
Every SMA therapy the NHS funds entered through a conditional route. Nusinersen and risdiplam sat in time-limited managed access from 2019 until TA1162 moved them to routine commissioning. UK SMA pricing is a question of how long an asset stays conditional.
Three NICE technology appraisals (TA606, TA738, TA1101) each carry a confidential Patient Access Scheme. Garadacimab's published £20,625 per-pen price is the only fully transparent figure in the class, and two MHRA-licensed agents still have no NICE-confirmed net price.
Rare disease is the most attractive place in pharma to launch a drug, and one of the hardest to size. Both facts have the same cause: a small, hidden, genetic population. Which is why you do not measure a rare-disease market. You build one.
Read →A single rare-disease indication looks like one market and behaves like several. Genotype, organ, or antibody status splits the population into groups that cannot be added together. Sizing the indication as one number counts patients no single therapy can reach.
Read →When a rare disease enters a newborn-screening panel, it stops being a prevalent pool to penetrate and becomes an incident flow plus a depleting backlog. Market size becomes a function of screening coverage, a policy variable, not epidemiology.
Read →In the Gulf, consanguinity enlarges the recessive-disease pool and state-run screening turns patient identification into a policy lever a forecaster can read. It is a distinct market, not a scaled-down Western one, and modelling it as the latter gets the number wrong in both directions.
Read →A one-time gene therapy sells to the patients who already have the diagnosis, and once that backlog is treated, to almost no one. Novartis' own CEO called it a bolus. It is why chronic-drug forecasting misreads the gene-therapy opportunity.
Read →Most pharma CI spend buys capability, a dashboard or a subscription, not the answer to a specific question. Four tests separate a competitive-intelligence brief you can act on from one you file.
Read →IgA nephropathy went from supportive care only to five approved drugs across four mechanisms in four years. The competitive question has inverted: no longer which drug is best, but where each fits in a treatment sequence no guideline has written.
Read →A rare-disease price of hundreds of thousands a year, or a gene therapy in the millions, does not fit the cost-effectiveness thresholds built for common disease. The HTA bodies have conceded it by writing a separate rulebook, and for a one-time cure the payment model breaks too.
Read →In most rare diseases the diagnosed population is a fraction of the true one, so a forecast anchored to who is coded today understates the market that exists. ATTR amyloidosis shows why the undiagnosed pool is not a caveat on the number. It is the number.
Read →Field-force sizing is where commercial spend concentrates — and the wrong method burns it. The three sizing approaches, and how a drug's commercial archetype decides which one is right.
Read →